Research Article Details
| Article ID: | A20877 |
| PMID: | 25670619 |
| Source: | Arab J Gastroenterol |
| Title: | Effects of fenugreek, Nigella, and termis seeds in nonalcoholic fatty liver in obese diabetic albino rats. |
| Abstract: | BACKGROUND AND STUDY AIM: Nonalcoholic fatty liver disease (NAFLD) occurs in approximately 80% of cases of type 2 diabetes mellitus (T2DM). This study investigated the effects of some plants used in Saudi Arabia as antidiabetic agents on T2DM and associated fatty liver. MATERIALS AND METHODS: A total of 150 adult male albino rats were divided into six experimental groups, each consisting of 25 rats. Twenty-five rats were considered as the control group. Experimental diabetes was induced in the remaining rats by administering a subcutaneous injection of 120 mg/kg of freshly prepared alloxan solution; these rats were classified into five groups: one group did not receive any treatment; the second group was treated with an aqueous extract of a mixture containing fenugreek, Nigella, and termis seeds; the third group was treated with an aqueous extract of Nigella sativa seeds; the fourth group was treated with an aqueous extract of fenugreek seeds; and finally the fifth group was treated with an aqueous extract of termis seeds at a dose of 100 mg/kg body weight. After 4 weeks of treatment, biochemical parameters were calculated, including blood sugar and serum insulin levels. Pancreatic and liver samples were obtained and processed for microscopic evaluation. RESULTS: The usage of each plant alone or a mixture of the plants corrected the glucose and insulin levels. Microscopically, a definite improvement in the number and diameter of β-cells in the diabetic group was observed. Furthermore, considerable improvement in fatty changes occurring in the liver of experimental animals was observed. The activity of the mixture was the most effective. CONCLUSIONS: The aqueous extract of the seed mixture of the used plants appeared to be a useful agent in improving fatty changes in the liver texture associated with T2DM by reducing hyperglycaemia through an increase in insulin levels, regeneration of β-cells of the pancreas, and an amelioration of associated dyslipidemia. |
| DOI: | 10.1016/j.ajg.2014.12.003 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I13 | 3146 | Lipid metabolism disorder | An inherited metabolic disorder that involves the creation and degradation of lipids. http://en.wikipedia.org/wiki/Lipid_metabolism | disease of metabolism/ inherited metabolic disorder | Details |
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D545 | Pig placenta extract | Biological extract | -- | -- | -- | Under clinical trials | Details |
| D135 | Fenugreek | Biological extract | -- | -- | -- | Under clinical trials | Details |
| D328 | Serine | Chemical drug | DB00133 | SRR | Improve insulin resistance | Under clinical trials | Details |
| D044 | Black cumin | Herbal medicine | -- | -- | -- | Under clinical trials | Details |
| D242 | Nigella Sativa | Biological extract | -- | -- | Gastrointestinal drug | Under clinical trials | Details |
| D083 | CLA | Chemical drug | DB01211 | KCNH2; SLCO1B1; SLCO1B3 | -- | Under clinical trials | Details |
| D182 | Insulin | Biological drug | DB00030 | INSR agonist; CPE modulator&product of | -- | Under clinical trials | Details |
| D248 | Obeticholic Acid | Chemical drug | DB05990 | NR1H4 activator; NR1H4 agonist; FXR agonist | Enhance lipid metabolism | Approval rejected | Details |
| D316 | S-adenosyl-L-methionine | Chemical drug | DB00118 | GNMT cofactor | Antiviral | Under clinical trials | Details |